Celularity (CELU)
NASDAQ:CELU
Want to see CELU full AI Analyst Report?
CELU Stock Chart & Stats
$1.25
-$0.06(-2.69%)
At close: 4:00 PM EST
$1.25
-$0.06(-2.69%)
Day’s Range― - ―
52-Week Range$0.71 - $4.35
Previous Close$2.13
Volume115.00K
Average Volume (3M)206.82K
Market Cap
$28.69M
Enterprise Value$58.56M
Total Cash (Recent Filing)$6.17M
Total Debt (Recent Filing)$40.90M
Price to Earnings (P/E)―
Beta3.02
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding28,945,961
10 Day Avg. Volume277,262
30 Day Avg. Volume206,824
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap2.04
Enterprise Value/Revenue2.21
Enterprise Value/Gross Profit2.90
Enterprise Value/Ebitda-0.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Bulls Say, Bears Say
Bulls Say
Asset MonetizationThe closed NexGel asset sale delivers immediate non-dilutive cash, milestone upside and retired ~ $13M of debt. This materially improves near-term liquidity and reduces leverage, enabling management to reallocate capital toward core cell-therapy R&D and extend runway while preserving upside.
Manufacturing & RoyaltiesBy licensing commercial biomaterials while retaining manufacturing rights and royalty economics, Celularity preserves a recurring margin stream and manufacturing control. This structure reduces commercial overhead, keeps upside via royalties, and concentrates resources on advancing higher-value clinical programs.
Narrowing Cash BurnOperating cash outflows have meaningfully narrowed versus earlier years and gross profit remained positive in 2024, indicating improving operational efficiency. Sustained burn reduction increases flexibility for clinical investment and lowers near-term financing frequency if trends continue.
Bears Say
Balance Sheet WeaknessNegative equity in 2025 and roughly flat debt levels signal a structurally weak capital base. This elevated leverage reduces financial flexibility, heightens refinancing and covenant risk, and increases the odds of dilution or onerous financing terms when securing future capital for clinical programs.
Persistent Cash BurnDespite improvement, operating and free cash flows are still negative, making the company dependent on external financing to fund operations and clinical development. Continued reliance on outside capital constrains strategic options and raises execution risk for multi-year clinical programs.
Financing & Governance RiskThe convertible exchange and competing default notice tied to a late 10-K create tangible financing and compliance risk. Potential penalties, accelerated obligations or higher interest amplify refinancing costs, while concurrent senior departures increase execution and governance risk during a critical strategic pivot.
Celularity News
CELU FAQ
What was Celularity’s price range in the past 12 months?
Celularity lowest stock price was $0.71 and its highest was $4.35 in the past 12 months.
What is Celularity’s market cap?
Celularity’s market cap is $28.69M.
When is Celularity’s upcoming earnings report date?
Celularity’s upcoming earnings report date is Apr 01, 2027 which is in 306 days.
How were Celularity’s earnings last quarter?
Currently, no data Available
Is Celularity overvalued?
According to Wall Street analysts Celularity’s price is currently Overvalued.
Does Celularity pay dividends?
Celularity does not currently pay dividends.
What is Celularity’s EPS estimate?
Celularity’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celularity have?
Celularity has 28,945,961 shares outstanding.
What happened to Celularity’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Celularity?
Currently, no hedge funds are holding shares in CELU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Technical Analysis
Ownership Overview
36.47% Insiders
2.63% Mutual Funds
3.16% Other Institutional Investors
55.42% Public Companies and
Individual Investors